Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

被引：298

作者：

Cuzick, J. ^{[1
]}

Berney, D. M. ^{[2
]}

Fisher, G. ^{[1
]}

Mesher, D. ^{[1
]}

Moller, H. ^{[3
]}

Reid, J. E. ^{[4
]}

Perry, M. ^{[4
]}

Park, J. ^{[4
]}

Younus, A. ^{[4
]}

Gutin, A. ^{[4
]}

Foster, C. S. ^{[5
]}

Scardino, P. ^{[6
]}

Lanchbury, J. S. ^{[4
]}

Stone, S. ^{[4
]}

机构：

[1] Univ London, Wolfson Inst Prevent Med, Ctr Canc Prevent, London EC1M 6BQ, England

[2] Univ London, Barts Canc Inst, Dept Mol Oncol, London EC1M 6BQ, England

[3] Kings Coll London, Thames Canc Registry, London SE1 3QD, England

[4] Myriad Genet Inc, Salt Lake City, UT 84108 USA

[5] Univ Liverpool, Dept Cellular Pathol & Mol Genet, Liverpool L1 3GA, Merseyside, England

[6] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA

来源：

BRITISH JOURNAL OF CANCER | 2012年 / 106卷 / 06期

基金：

美国国家卫生研究院;

关键词：

localised prostate cancer; prognostic factors; cell cycle genes; expression profiles; CCP score; needle biopsy; INTRAEPITHELIAL NEOPLASIA; LATENT CARCINOMA; AUTOPSY; PREVALENCE; SPECIMENS;

D O I：

10.1038/bjc.2012.39

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by transurethral resection of the prostate. A greater need is to predict outcome in patients diagnosed by needle biopsy. METHODS: Total RNA was extracted from paraffin specimens. A CCP score was calculated from expression levels of 31 genes. Clinical variables consisted of centrally re-reviewed Gleason score, baseline prostate-specific antigen level, age, clinical stage, and extent of disease. The primary endpoint was death from prostate cancer. RESULTS: In univariate analysis (n = 349), the hazard ratio (HR) for death from prostate cancer was 2.02 (95% CI (1.62, 2.53), P<10(-9)) for a one-unit increase in CCP score. The CCP score was only weakly correlated with standard prognostic factors and in a multivariate analysis, CCP score dominated (HR for one-unit increase = 1.65, 95% CI (1.31, 2.09), P = 3 x 10(-5)), with Gleason score (P = 5 x 10(-4)) and prostate-specific antigen (PSA) (P = 0.017) providing significant additional contributions. CONCLUSION: For conservatively managed patients, the CCP score is the strongest independent predictor of cancer death outcome yet described and may prove valuable in managing clinically localised prostate cancer. British Journal of Cancer (2012) 106, 1095-1099. doi:10.1038/bjc.2012.39 www.bjcancer.com Published online 23 February 2012 (C) 2012 Cancer Research UK

引用

页码：1095 / 1099

页数：5

共 18 条

[1]

[Anonymous], 2010, International statistical classification of diseases and related health problems, 10th revision

[2] LATENT CARCINOMA AND ATYPICAL LESIONS OF PROSTATE - AN AUTOPSY STUDY [J].

BILLIS, A .

UROLOGY, 1986, 28 (04) :324-329

[3]

Brawley OW, 1997, CANCER-AM CANCER SOC, V80, P1857, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO

[4]

2-3

[5] LATENT CARCINOMA OF PROSTATE AT AUTOPSY IN 7 AREAS - COLLABORATIVE STUDY ORGANIZED BY INTERNATIONAL-AGENCY-FOR-RESEARCH-ON-CANCER, LYONS, FRANCE [J].

BRESLOW, N ;

CHAN, CW ;

DHOM, G ;

DRURY, RAB ;

FRANKS, LM ;

GELLEI, B ;

LEE, YS ;

LUNDBERG, S ;

SPARKE, B ;

STERNBY, NH ;

TULINIUS, H .

INTERNATIONAL JOURNAL OF CANCER, 1977, 20 (05) :680-688

[6] Screening for Prostate Cancer: A Review of the Evidence for the US Preventive Services Task Force [J].

Chou, Roger ;

Croswell, Jennifer M. ;

Dana, Tracy ;

Bougatsos, Christina ;

Blazina, Ian ;

Fu, Rongwei ;

Gleitsmann, Ken ;

Koenig, Helen C. ;

Lam, Clarence ;

Maltz, Ashley ;

Rugge, J. Bruin ;

Lin, Kenneth .

ANNALS OF INTERNAL MEDICINE, 2011, 155 (11) :762-U94

[7] Long-term outcome among men with conservatively treated localised prostate cancer [J].

Cuzick, J. ;

Fisher, G. ;

Kattan, M. W. ;

Berney, D. ;

Oliver, T. ;

Foster, C. S. ;

Moller, H. ;

Reuter, V. ;

Fearn, P. ;

Eastham, J. ;

Scardino, P. .

BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1186-1194

[8] Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study [J].

Cuzick, Jack ;

Swanson, Gregory P. ;

Fisher, Gabrielle ;

Brothman, Arthur R. ;

Berney, Daniel M. ;

Reid, Julia E. ;

Mesher, David ;

Speights, V. O. ;

Stankiewicz, Elzbieta ;

Foster, Christopher S. ;

Moller, Henrik ;

Scardino, Peter ;

Warren, Jorja D. ;

Park, Jimmy ;

Younus, Adib ;

Flake, Dart D., II ;

Wagner, Susanne ;

Gutin, Alexander ;

Lanchbury, Jerry S. ;

Stone, Steven .

LANCET ONCOLOGY, 2011, 12 (03) :245-255

[9]

Etzioni R, 2002, J NATL CANCER I, V94, P981

[10] WHICH PATIENTS ARE CURED OF BREAST-CANCER [J].

FENTIMAN, IS ;

CUZICK, J ;

MILLIS, RR ;

HAYWARD, JL .

BRITISH MEDICAL JOURNAL, 1984, 289 (6452) :1108-1111

← 1 2 →